EAACI Congress 2024
BackAllergen immunotherapy 7
Sunday 02 Jun, 12:00 PM -
13:00 PM Valencia, Spain
Poster Zone
Thematic Poster Session
12:00
Allergenic identification and characterization of holm oak (Quercus ilex) pollen
12:00
Allergy in paediatrics: a current overview on paediatric allergists of Spain, Portugal and Italy
12:00
Development of monoclonal antibodies against dog allergens and their application for the analysis of dog allergen extracts
12:00
Emotional experience of respiratory allergy patient journey: focus on the first specialist consultation
12:00
Evaluation of the efficacy, adverse effects, and cost-effectiveness of sublingual immunotherapy with dominant allergens for allergic rhinitis due to respiratory allergens in adults and children
12:00
Improving Allergen-Immunotherapy: Practical Tools for Young Allergists
12:00
Meta-analysis of primary endpoint of PQ Grass field studies with optimized dose and treatment regimen of PQ Grass
12:00
Positive outcome of the pivotal Phase III study with PQ Grass, a modified grass allergen subcutaneous immunotherapy (SCIT) product using MicroCrystalline Tyrosine and Monophosphoryl Lipid A as adjuvant system
12:00
Real-world study: safety and effectiveness of a subcutaneous glutaraldehyde, polymerized undiluted D.pteronyssinus-D.farinae allergen extract
12:00
Secondary endpoint profile is strongly supportive for the positive outcome of the pivotal Phase III study with PQ Grass
12:00
Short-term benefits of sublingual immunotherapy in routine clinical practice: deciphering factors influencing the patient satisfaction in the observational, prospective, longitudinal study PRACTIS
12:00
Spreading of sensitization to airborne allergens in patients under AIT
12:00
Stability of an allergoid with a mixture of Dermatophagoides pteronyssinus and dog dander
